Table 1. Vaccine candidate targets against trichomoniasis.

49. Smith JD, Garber GE (2015). Trichomonas vaginalis infection induces vaginal CD4+ T-cell infiltration in a mouse model: a vaccine strategy to reduce vaginal infection and HIV transmission. J Infect Dis 212(2): 285-93. 10.1093/infdis/jiv036

107. Yadav M, Dubey ML, Gupta I, Bhatti G, Malla N (2007). Cysteine proteinase 30 in clinical isolates of T. vaginalis from symptomatic and asymptomatic infected women. Exp Parasitol 116(4): 399-406. 10.1016/j.exppara.2007.02.007

108. Hernández HM, Figueredo M, Garrido N, Sánchez L, Sarracent J (2005). Intranasal immunisation with a 62 kDa proteinase combined with cholera toxin or CpG adjuvant protects against Trichomonas vaginalis genital tract infections in mice. Int J Parasitol 35(13): 1333-7. 10.1016/j.ijpara.2005.08.010

111. Xie YT, Gao JM, Wu YP, Tang P, Hide G, Lai DH, Lun ZR (2017). Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis. Parasit Vectors 10(1): 83. 10.1186/s13071-017-2009-8

112. Mendoza-Oliveros T, Arana-Argáez V, Alvaréz-Sánchez LC, Lara-Riegos J, Alvaréz-Sánchez ME, Torres-Romero JC (2019). Immune Response of BALB/c Mice toward Putative Calcium Transporter Recombinant Protein of Trichomonas vaginalis. Korean J Parasitol 57(1): 33-38. 10.3347/kjp.2019.57.1.33

113. Mirasol-Meléndez E, Brieba LG, Díaz-Quezada C, López-Hidalgo M, Figueroa-Angulo EE, Ávila-González L, Arroyo-Verástegui R, Benítez-Cardoza CG (2018). Characterization of multiple enolase genes from Trichomonas vaginalis. Potential novel targets for drug and vaccine design. Parasitol Int 67(4): 444-453. 10.1016/j.parint.2018.04.003

114. Barajas-Mendiola MA, Castellano LE, Barrios-Rodiles M, Deveze-Alvarez MA, Avila EE, Cuéllar-Mata P (2019). Reduced Trichomonas vaginalis viability in mice pretreated with parasite DNA. Parasitology 146(13): 1636-1645. 10.1017/S0031182019001094